Cyanoacetic acid → HCID 136342279, compound
Reaction equation
Cl.[NH:2]1[CH2:7][CH2:6][CH2:5][C@@H:4]([C:8]2[N:12]3[C:13]4[CH:19]=[CH:18][NH:17][C:14]=4[N:15]=[CH:16][C:11]3=[N:10][N:9]=2)[CH2:3]1.[C:20]([CH2:22][C:23](O)=[O:24])#[N:21].C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.Cl.CCN(C(C)C)C(C)C>CN(C=O)C>[C:8]1([C@@H:4]2[CH2:5][CH2:6][CH2:7][N:2]([C:23](=[O:24])[CH2:22][C:20]#[N:21])[CH2:3]2)[N:12]2[C:13]3[CH:19]=[CH:18][NH:17][C:14]=3[N:15]=[CH:16][C:11]2=[N:10][N:9]=1Participants
7
Reactant 5
Product 1
Reagents, catalysts & solvents 1
Procedure
To a suspension of (R)-1-(piperidin-3-yl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazine hydrochloride (0.074 g, 0.265 mmol; Example #I1.1) and 2-cyanoacetic acid (0.034 g, 0.398 mmol) in DMF (3 mL) was added HOBt (0.041 g, 0.265 mmol), EDC.HCl (0.051 g, 0.265 mmol) and DIEA (0.093 mL, 0.531 mmol). The reaction mixture was stirred at ambient temperature for about 16 h. The crude reaction mixture was purified by RP-HPLC (Table 2, Method f). The appropriate fractions were concentrated in vacuo and lyophilized to afford (R)-3-(3-(6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-1-yl)piperidin-1-yl)-3-oxopropanenitrile as a white solid (0.052 g, 63%): LC/MS (Table 2, Method a) Rt=1.30 min; MS m/z: 310 (M+H)+.
Workup
- customThe crude reaction mixture
- customwas purified by RP-HPLC (Table 2, Method f)
- concentrationThe appropriate fractions were concentrated in vacuo
Sources & evidence
- ORD record
- ord-0b907239b4ea46ecb05f619fcb7aa564
- Source dataset
- uspto-grants-2015_02
- Patent number
- US08962629B2
Reaction notes
Loading…